Issue link: https://www.e-digitaleditions.com/i/1521797
Inhalation June 2024 15 Trends and challenges in the nasal powder drug market Market entry challenges At present, there are only a limited number of nasal powder products available. eir indications range from treating migraine to rhinitis to diabetes. Table 2 summarizes the current nasal powder products, high- lighting their indications, development stages and geographical availability. dynamic vapor sorption and rheological assessment. ese tools were utilized to screen and optimize mucoadhesive excipients in a nasal powder [29]. All these methodologies can be utilized to better predict a product's clinical performance and are crucial for optimizing delivery and efficacy. Molecule Type Active Pharmaceutical Ingredient Indications Phases Country/ Region Small Molecule Beclomethasone dipropionate Allergic rhinitis Marketed Japan Sumatriptan succinate Migraine Marketed United States Dexamethasone cipecylate Allergic rhinitis Marketed South Korea, Japan Dexamethasone cipecylate Allergic rhinitis Marketed Japan Levodopa Parkinson's Phase 2 Olanzapine Agitation Phase 2 Dihydroergotamine mesylate Migraine Phase 3 United States Naloxone hydrochloride Opioid dependence Registration United States Naloxone hydrochloride dihydrate Opioid dependence Phase 3 Protein Allergen, Lofarma Allergic rhinoconjunctivitis Marketed Europe Glucagon Diabetes, Hypoglycemia Marketed United States Diabetes, Hypoglycemia Marketed Europe Diabetes, Hypoglycemia Marketed Japan Diabetes, Hypoglycemia Marketed Canada Carbohydrate Hydroxypropyl methylcellulose Infections Marketed Europe, Canada, Americas Latin Infections Marketed Asia Infections Marketed Asia, Africa Oligonucleotide Polyriboinosinic and Polyribocytidylic acid (a synthetic dsDNA) Infections, Rhinovirus Phase 2 UK Asthma Phase 2 Infections, Influenza Phase 2 Infections, Rhinovirus Phase 2 Table 2 Representative Marketed and Developmental Nasal Powder Products (Search conducted on PharmaCircle, December 18, 2023)